RealTimeTouch.com RealTimeTouch.com Patent US9639150 RealTimeTouch.com message RealTimeTouch.com RealTimeTouch.com



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




RealTimeTouch.com RealTimeTouch.com Patent US9639150 RealTimeTouch.com message RealTimeTouch.com RealTimeTouch.com

Similar
Filing Names

Ucb Pharma S a
Ucb Pharma S a_20100114
Ucb Pharma S a_20131212
Ucb Pharma S a_20100121
  

Ucb Pharma S a patents

Recent patent applications related to Ucb Pharma S a. Ucb Pharma S a is listed as an Agent/Assignee. Note: Ucb Pharma S a may have other listings under different names/spellings. We're not affiliated with Ucb Pharma S a, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "U" | Ucb Pharma S a-related inventors




Date Ucb Pharma S a patents (updated weekly) - BOOKMARK this page
12/08/16Antibody molecules having specificity for human ox40
11/17/16Multivalent antibodies
10/27/16Dual specificity antibody fusions
09/01/16Neutralising antibody molecules having specificity for human il-17
07/14/16Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
07/14/16Bacterial host strain
07/07/16Therapeutically active pyrazolo-pyrimidine derivatives
06/30/16Compositions and methods for increasing bone mineralization
06/30/16Compounds for enhancing the cognitive function
04/21/16Protein purification
12/03/15Bacterial host strain
11/12/15Nucleic acids encoding antibody molecules which bind il-17a and il-17f
11/05/15Epitopes of il-17a and il-17f and antibodies specific thereto
10/01/15Disulfide stabilised antibodies and fragments thereof
08/06/15Method for identifying compounds of therapeutic interest
07/09/15Antibodies specific for sclerostin and methods for increasing bone mineralization
06/25/15Syringe safety assembly
06/18/15Bacterial host strain comprising a mutant spr gene and a wild-type tsp gene
06/18/15Bacterial host strain expressing recombinant dsbc and having reduced tsp activity
06/11/15Methods for treating parkinson's disease
06/04/15Pharmaceutical formulation
05/28/15Neutralising antibody molecules having specificity for human il-17
05/21/15Systems for automatically administering medication
05/14/15Bacterial host strain comprising a mutant spr gene and having reduced tsp activity
04/23/15Recombinant bacterial host cell for protein expression
01/22/15Method for producing protein
01/15/15Sequence asymmetric modified igg4 bispecific antibodies
01/15/15Sequence symmetric modified igg4 bispecific antibodies
01/08/152-oxo-piperidinyl derivatives
12/04/14Method for producing protein
11/27/14Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
11/20/14Dna encoding function modifying nav1.7 antibodies
10/16/14Therapeutically active fused pyrimidine derivatives
10/09/14Albumin binding antibodies and binding fragments thereof
09/11/14Systems and methods for administering medication
08/28/14Analytical fab and fab' molecules
07/10/14Epitopes of il-17a and il-17f and antibodies specific thereto
07/10/14Dual specificity antibody fusions
07/03/14Nucleic acids encoding antibody molecules which bind il-17a and il-17f
06/26/14Antibody molecules having binding specificity for human il-13
05/29/142-oxo-1-imidazolidinyl imidazothiadiazole derivatives
05/22/14Bacterial host strain expressing recombinant dsbc
03/20/14Lipocalin 2 as a biomarker for il-17 inhibitor therapy efficacy
03/06/14Antibody molecules which bind il-17a and il-17f
02/13/14Nucleic acids encoding antibody molecules which bind il-17a and il-17f
01/30/14Treatment for bone diseases
01/23/14Antibody molecules having specificity for human il-6
12/12/13Antibody molecules having specificity for human ox40
12/05/13Antibodies of the class igg4
11/14/13Disulfide stabilized dvd-ig molecules
11/07/13Quinoline and quinoxaline derivatives as kinase inhibitors
09/19/13Antibody molecules having specificity for human ox40
09/19/13Neutralising antibody molecules having specificity for human il-17
07/18/13Analytical fab and fab' molecules
07/18/13Protein purification
07/11/13Process for purifying proteins
06/13/13Thieno-pyridine derivatives as mek inhibitors
05/02/13Disulfide stabilized antibodies and fragments thereof
04/25/13Antibody molecules which bind il-17a and il-17f
04/18/13Pd-1 antibody
03/28/13Syringe safety assembly
03/28/13Fused thiazole derivatives as kinase inhibitors
03/14/13Multivalent antibodies
02/21/13Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
01/17/13Quinoline and quinoxaline derivatives as kinase inhibitors
Patent Packs
01/10/13Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
01/10/13Quinoline and quinoxaline derivatives as kinase inhibitors
12/27/12Thieno-pyridine derivatives as mek inhibitors
12/13/12Disulfide stabilised multivalent antibodies
11/29/12Bacterial host strain comprising a mutant spr gene and a wild-type tsp gene
11/29/12Novel process for the preparation of nitrogen substituted aminotetralins derivatives
11/22/12Bacterial host strain comprising a mutant spr gene and having reduced tsp activity
11/15/12Bacterial host strain expressing recombinant dsbc and having reduced tsp activity
11/08/12Multivalent antibodies
10/18/12Method to generate antibodies to ion channels
10/18/12Method to generate antibodies to ion channels
10/11/12Bacterial host strain
10/11/12Antibodies to ion channels
09/27/122-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
09/27/12Co-crystals of pyrrolidinones
Patent Packs
08/23/122-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
08/02/122-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
07/19/12Antibody molecules which bind il-17a and il-17f
07/05/12Methods for enhancing the cognitive function
05/24/12Antibody molecules which bind human il-17
04/19/12Method for producing protein
04/19/12Fused bicyclic pyrazole derivatives as kinase inhibitors
03/29/12Fused pyridine and pyrazine derivatives as kinase inhibitors
03/01/12Triazine derivatives as kinase inhibitors
02/16/12Method for producing proteins
02/16/12Pharmaceutical compositions comprising brivaracetam
02/09/12Neutralising antibody molecules having specificity for human il-17
02/02/12Substituted aniline derivatives
12/22/11Method for producing proteins
12/15/11Epitopes
11/17/11Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
11/10/11Antibody-guided fragment growth
11/10/11Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
11/10/11Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
10/27/11Epitopes of il-17a and il-17f and antibodies specific thereto
10/13/11Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
08/18/11Fused pyridine derivatives as kinase inhibitors
07/28/11Biological products
07/14/11Thieno-pyridine derivatives as mek inhibitors
05/05/11Quinoxaline and quinoline derivatives as kinase inhibitors
04/28/11Binding agents
04/28/11Compounds comprising a cyclobutoxy group
04/21/11Pharmaceutical compositions comprising brivaracetam
03/17/11Extended release formulation of levetiracetam
03/17/11Extended release formulation of levetiracetam
Social Network Patent Pack
01/27/11Thieno-pyridine derivatives as mek inhibitors
01/27/11Pharmaceutical solutions, process of preparation and therapeutic uses
01/20/11Substituted aniline derivatives
01/06/11Fused thiazole derivatives as kinase inhibitors
12/09/10Method for the treatment of glomerulonephritis
12/02/10Fused thiophene derivatives as kinase inhibitors
12/02/10Compounds comprising a cyclobutoxy group
11/25/10Thiazole derivatives as kinase inhibitors
11/25/10Heterobicyclic compounds as histamine h4-receptor antagonists
11/18/10Compounds comprising a cyclobutoxy group
Patent Packs
11/18/10Sulfanyl derivatives and their use as synthesis intermediates
11/11/10E.coli host cells with modified phos/psts periplasmic phosphate-binding proteins, and manufacturing recombinant fabs
10/21/10Antibody molecules which bind il-17a and il-17f
09/23/10Dual specificity antibody fusions
09/23/10Co-crystals of pyrrolidinones
09/02/10New heterocyclic derivatives useful for the treatment of cns disorders
07/15/10Thieno-pyridine derivatives as mek inhibitors
07/15/10Novel aminothienopyridinone derivatives processes for preparing them and pharmaceutical compositions thereof
07/01/10Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
06/24/10Antibody molecules having specificity for human il-1b
06/03/10Fused thiazole derivatives as kinase inhibitors
04/15/10Altered antibodies
04/08/10Antibody molecules which bind to human il-17
03/18/10Fused thiazole derivatives as kinase inhibitors
03/18/10Indolone-acetamide derivatives, processes for preparing them and their uses
02/11/10Antibody-based diagnostics and therapeutics
02/11/102 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
01/21/10Antibodies and diagnostics
01/14/10Fused oxazoles & thiazoles as histamine h3- receptor ligands
12/31/09Framework selection
12/17/092-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
12/10/09Single chain fc polypeptides
12/10/09Binding agents
10/22/09Fused thiophene derivatives as mek inhibitors
09/24/09Expression control using antibody expression optimisation sequences
09/03/09Process for preparing 1-halo-2,7-naphthyridinyl derivatives
07/23/09Phenylalanine enamide derivatives
06/11/09Thieno-pyridine derivatives as mek inhibitors
05/21/09Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
05/14/09Bioassays
Patent Packs
05/07/09Neutralising antibody molecules having specificity for human il-17
03/19/09Method for obtaining antibodies
12/12/13Antibody molecules having specificity for human ox40
01/21/10Antibodies and diagnostics
01/14/10Fused oxazoles & thiazoles as histamine h3- receptor ligands







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ucb Pharma S a in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ucb Pharma S a with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';